Lieff Cabraser partners Wendy R. Fleishman and Sarah R. London will be speaking at HarrisMartin’s “JUUL, E-Cigarettes & Vaping Conference: Emerging Litigation and Liability Theories Agenda,” at the Four Seasons Hotel in St. Louis on Wednesday, September 18, 2019. Wendy will be discussing the marketing of e-cigarettes to teens and children in a presentation entitled “JUUL and Our Kids: Marketing and Promoting the JUUL Device From ‘Vaporized’ to ‘Make the Switch.’” [Read more…]
Multiple Lieff Cabraser attorneys will be participating in HarrisMartin’s Southern California Wildfires and Mudslide Litigation Conference on May 8, 2018 at The Ritz-Carlton in Marina del Ray, California. [Read more…]
Lieff Cabraser partner Mark P. Chalos will be speaking about the opioid epidemic and related lawsuits at HarrisMartin’s MDL Conference: Orthopedic Devices and Hernia Mesh Litigation on September 27, 2017 at the Hotel Commonwealth in Boston. Mr. Chalos will participate on the panel entitled “Mass Tort Quick Hits” from 5:00-5:45pm. [Read more…]
Lieff Cabraser attorney Lexi J. Hazam will be a featured panelist at HarrisMartin’s National Opioid Litigation Conference on October 3, 2017 in Chicago, Illinois. Ms. Hazam will be speaking on a panel titled “Who are the Governmental Action Plaintiffs and What are the Causation Theories?” [Read more…]
Lieff Cabraser attorney Lexi J. Hazam is speaking at HarrisMartin’s MDL Conference: Zofran, Bard IVC and Zimmer Persona Knee Litigation on July 29, 2015 at Hotel Nikko in San Francisco. Hazam will be featured as a panelist discussing the Benicar (Olmesartan) Litigation. Hazam has been appointed by the court overseeing the nationwide Benicar MDL litigation to the Plaintiffs’ Steering Committee, and serves as Co-Chair of the MDL Plaintiffs’ Science and Experts Committee.
Lieff Cabraser attorney Lexi J. Hazam will be speaking at HarrisMartin’s MDL Conference: Xarelto, Morcellators and Emerging Torts on March 25, 2015 at The Westin San Diego. Hazam will be featured on a panel discussing the prescription drug Benicar. Hazam will also be addressing the science behind the plaintiffs’ claims.